A multicenter phase II study evaluated the efficacy of everolimus, a mammalian target of rapamycin (mTOR) inhibitor that is important for proliferation signaling of the Akt pathway, in patients diagnosed with ACC in salivary glands. This evidence concerns the gene AKT1 and adrenal cortex carcinoma.